<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Insulin Glulisine</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01309</strong></td></tr><tr><th>Type</th><td>biotech</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Insulin glulisine is a biosynthetic, rapid-acting human insulin analogue produced in a non-pathogenic laboratory strain of <em>Escherichia coli</em> (K12). This recombinant hormone differs from native human insulin in that the amino acid arginine at position B3 is replaced by lysine and the lysine at position B29 is replaced by glutamic acid. These structural modifications decrease hexamer formation, stabilize insulin glulisine monomers and increase the rate of absorption and onset of action compared to human insulin.</p></td></tr><tr><th>Protein structure</th><td><img alt="No structure small" src="/assets/no_structure_small-e8790a148b09ecc5ad9f5b4926a538e7.png"></td></tr><tr><th>Protein chemical formula</th><td>C<sub>258</sub>H<sub>384</sub>N<sub>64</sub>O<sub>78</sub>S<sub>6</sub></td></tr><tr><th>Protein average weight</th><td>5823 Daltons </td></tr><tr><th>Sequences</th><td><pre class="sequence">&gt;A chain
GIVEQCCTSICSLYQLENYCN</pre><pre class="sequence">&gt;B chain
FVKQHLCGSHLVEALYLVCGERGFFYTPET</pre><small><a class="btn btn-info btn-sm" href="/drugs/DB01309/polypeptide_sequences.fasta">Download FASTA Format</a></small></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Apidra</td><td>Sanofi-Aventis</td></tr><tr><td>Apidra SoloStar </td><td>Sanofi-Aventis</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antidiabetic-agents">Antidiabetic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>207748-29-6</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of Type 1 and 2 diabetes mellitus. Should be used in regimens including a long-acting or basal insulin analogue unless it is used in a continuous infusion pump. May be used with oral antidiabetic agents. </td></tr><tr><th>Pharmacodynamics</th><td>Insulin is a natural hormone produced by beta cells of the pancreas. In non-diabetic individuals, a basal level of insulin is supplemented with insulin spikes following meals. Postprandial insulin spikes are responsible for the metabolic changes that occur as the body transitions from a postabsorptive to absorptive state. Insulin promotes cellular uptake of glucose, particularly in muscle and adipose tissues, promotes energy storage via glycogenesis, opposes catabolism of energy stores, increases DNA replication and protein synthesis by stimulating amino acid uptake by liver, muscle and adipose tissue, and modifies the activity of numerous enzymes involved in glycogen synthesis and glycolysis. Insulin also promotes growth and is required for the actions of growth hormone (e.g. protein synthesis, cell division, DNA synthesis). Insulin glulisine is a rapid-acting insulin analogue used to mimic postprandial insulin spikes in diabetic individuals. The onset of action of insulin glulisine is approximately 15 minutes. Its activity peaks 60 minutes following subcutaneous injection and its duration of action is 2-4 hours.</td></tr><tr><th>Mechanism of action</th><td>Insulin glulisine binds to the insulin receptor (IR), a heterotetrameric protein consisting of two extracellular alpha units and two transmembrane beta units. The binding of insulin to the alpha subunit of IR stimulates the tyrosine kinase activity intrinsic to the beta subunit of the receptor. The bound receptor autophosphorylates and phosphorylates numerous intracellular substrates such as insulin receptor substrates (IRS) proteins, Cbl, APS, Shc and Gab 1. Activation of these proteins leads to the activation of downstream signaling molecules including PI3 kinase and Akt. Akt regulates the activity of glucose transporter 4 (GLUT4) and protein kinase C (PKC), both of which play critical roles in metabolism and catabolism. In humans, insulin is stored in the form of hexamers; however, only insulin monomers are able to interact with IR. Substitution of the arginine at position B3 for lysine and replacement of the B29 lysine with glutamic acid decreases the propensity to form hexamers, stabilizes the hormone in monomeric form and results in a rapid rate of absorption and short duration of action. </td></tr><tr><th>Absorption</th><td>Compared to regular human insulin, insulin glulisine is faster absorbed. When 0.15 units/kg was subcutaneously administered to type 1 diabetes patients, the pharmacokinetic parameters are as follows:
Tmax = 60 minutes (range of 40 - 120 minutes);
Cmax = 83 microUnits/mL (range of 40 - 131 microUnits/mL). 
Absolute bioavailability following subcutaneous administration is approximately 70%, regardless of site of injection. </td></tr><tr><th>Volume of distribution</th><td><p>13 L</p></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>Elimination half life= 42 minutes (following subcutaneous injection)</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>Inappropriately high dosages relative to food intake and/or energy expenditure may result in severe and sometimes prolonged and life-threatening hypoglycemia. Neurogenic (autonomic) signs and symptoms of hypoglycemia include trembling, palpitations, sweating, anxiety, hunger, nausea and tingling. Neuroglycopenic signs and symptoms of hypoglycemia include difficulty concentrating, lethargy/weakness, confusion, drowsiness, vision changes, difficulty speaking, headache, and dizziness. Mild hypoglycemia is characterized by the presence of autonomic symptoms. Moderate hypoglycemia is characterized by the presence of autonomic and neuroglycopenic symptoms. Individuals may become unconscious in severe cases of hypoglycemia. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Sanofi aventis us llc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.sanofi-aventis.com">Sanofi-Aventis Inc.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, solution</td><td>Subcutaneous</td><td>100 units/ml</td></tr></tbody></table></td></tr><tr><th>Prices</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="prices"><thead><tr><th>Unit description</th><th>Cost</th><th>Unit</th></tr></thead><tbody><tr><td>Apidra 100 unit/ml cartridge</td><td>13.3USD</td><td>ml</td></tr><tr><td>Apidra 100 unit/ml Cartridge</td><td>3.56USD</td><td>cartridge</td></tr><tr><td>Apidra 100 unit/ml Syringe</td><td>3.56USD</td><td>syringe</td></tr><tr><td>Apidra 100 unit/ml</td><td>2.67USD</td><td>cartridge</td></tr></tbody></table><div class="alert alert-warning clearfix">DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.</div></td></tr><tr><th>Patents</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="patents"><thead><tr><th>Country</th><th>Patent Number</th><th>Approved</th><th>Expires (estimated)</th></tr></thead><tbody><tr><td>United States</td><td>6960561</td><td>2003-01-25</td><td>2023-01-25</td></tr><tr><td>United States</td><td>6221633</td><td>1998-06-18</td><td>2018-06-18</td></tr></tbody></table></td></tr><tr id="properties"><th class="divider" colspan="2">Properties</th></tr><tr><th>State</th><td>liquid</td></tr><tr><th>Experimental Properties</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="references"><th class="divider" colspan="2">References</th></tr><tr><th>Synthesis Reference</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>General Reference</th><td><span class="citations"><ol>
	<li>Arnolds S, Rave K, Hovelmann U, Fischer A, Sert-Langeron C, Heise T: Insulin Glulisine Has a Faster Onset of Action Compared with Insulin Aspart in Healthy Volunteers. Exp Clin Endocrinol Diabetes. 2010 Apr 28. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20429049">Pubmed</a></li>
	<li>Becker RH: Insulin glulisine complementing basal insulins: a review of structure and activity. Diabetes Technol Ther. 2007 Feb;9(1):109-21. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17316105">Pubmed</a></li>
	<li>Becker RH, Frick AD: Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet. 2008;47(1):7-20. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18076215">Pubmed</a></li>
	<li>Cox SL: Insulin glulisine. Drugs Today (Barc). 2005 Jul;41(7):433-40. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16193096">Pubmed</a></li>
	<li>Garnock-Jones KP, Plosker GL: Insulin glulisine: a review of its use in the management of diabetes mellitus. Drugs. 2009 May 29;69(8):1035-57. doi: 10.2165/00003495-200969080-00006. <a href="http://www.ncbi.nlm.nih.gov/pubmed/19496630">Pubmed</a></li>
	<li>Horvath K, Bock G, Regittnig W, Bodenlenz M, Wutte A, Plank J, Magnes C, Sinner F, Furst-Recktenwald S, Theobald K, Pieber TR: Insulin glulisine, insulin lispro and regular human insulin show comparable end-organ metabolic effects: an exploratory study. Diabetes Obes Metab. 2008 Jun;10(6):484-91. Epub 2007 Aug 30. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17764465">Pubmed</a></li>
	<li>Insuline glusine (Apidra): a new rapid-acting insulin. Med Lett Drugs Ther. 2006 Apr 24;48(1233):33-4. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16625142">Pubmed</a></li>
	<li>Robinson DM, Wellington K: Insulin glulisine. Drugs. 2006;66(6):861-9. <a href="http://www.ncbi.nlm.nih.gov/pubmed/16706558">Pubmed</a></li>
	<li>Ulrich H, Snyder B, Garg SK: Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine. Vasc Health Risk Manag. 2007;3(3):245-54. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17703632">Pubmed</a></li>
</ol></span></td></tr><tr><th>External Links</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Resource</th><th>Link</th></tr></thead><tbody><tr><td>PharmGKB</td><td><a class="wishart-link-out" href="http://www.pharmgkb.org/drug/PA164760859" target="_blank">PA164760859 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>RxList</td><td><a class="wishart-link-out" href="http://www.rxlist.com/apidra-drug.htm" target="_blank">http://www.rxlist.com/apidra-drug.htm <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Drugs.com</td><td><a class="wishart-link-out" href="http://www.drugs.com/mtm/insulin-glulisine.html" target="_blank">http://www.drugs.com/mtm/insulin-glulisine.html <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>PDRhealth</td><td><a class="wishart-link-out" href="http://www.pdrhealth.com/drugs/rx/rx-mono.aspx?contentFileName=api1806.html&amp;contentName=Apidra&amp;contentId=70" target="_blank">http://www.pdrhealth.com/drugs/rx/rx-mono.aspx?contentFileName=api1806.html&amp;contentName=Apidra&amp;contentId=70 <span class="glyphicon glyphicon-new-window"> </span></a></td></tr><tr><td>Wikipedia</td><td><a class="wishart-link-out" href="http://en.wikipedia.org/wiki/Insulin_glulisine" target="_blank">Insulin_glulisine <span class="glyphicon glyphicon-new-window"> </span></a></td></tr></tbody></table></td></tr><tr><th>ATC Codes</th><td>A10AB06<ul class="atc-drug-tree"><li><a href="/atc/A#A">A &#8212; ALIMENTARY TRACT AND METABOLISM</a></li><li><a href="/atc/A10#A10">A10 &#8212; DRUGS USED IN DIABETES</a></li><li><a href="/atc/A10A#A10A">A10A &#8212; INSULINS AND ANALOGUES</a></li><li><a href="/atc/A10AB#A10AB">A10AB &#8212; Insulins and analogues for injection, fast-acting</a></li></ul></td></tr><tr><th>AHFS Codes</th><td><ul><li>68:20.08</li></ul></td></tr><tr><th>PDB Entries</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>FDA label</th><td><a href="/system/fda_labels/DB01309.pdf?1372140360">show</a>(1.67 MB)</td></tr><tr><th>MSDS</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01193">Acebutolol</a></td><td>The beta-blocker, acebutolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00335">Atenolol</a></td><td>The beta-blocker, atenolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00612">Bisoprolol</a></td><td>The beta-blocker, bisoprolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB01136">Carvedilol</a></td><td>The beta-blocker, carvedilol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00636">Clofibrate</a></td><td>Increases the effect of insulin</td></tr><tr><td><a href="/drugs/DB01191">Dexfenfluramine</a></td><td>Fenfluramine increases the effect of insulin</td></tr><tr><td><a href="/drugs/DB00187">Esmolol</a></td><td>The beta-blocker, esmolol, may decrease symptoms of hypoglycemia.</td></tr><tr><td><a href="/drugs/DB00574">Fenfluramine</a></td><td>Fenfluramine increases the effect of insulin</td></tr><tr><td><a href="/drugs/DB00052">Somatropin recombinant</a></td><td>Somatropin may antagonize the hypoglycemic effect of insulin glulisine. Monitor for changes in fasting and postprandial blood sugars.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>